Advancing Discovery Faster and Cheaper by Enabling Collaborative Research

Foundations are created for a cause. However the research they fund towards the cause, and ensuing knowledge, in most cases, gets siloed. CytoSolve puts together that knowledge, using a patient-centered approach, thus driving a 21st century way of doing medicine.

Our leadership has addressed and educated major foundations across the world on the power of CytoSolve and its Systems-Based approach

Upcoming Event

State of the Art Lecture

Title: In Silico Mechanistic Modeling: The Future of Precision Medicine


Date: Saturday, Mar 18, 2017, 9:15 am – 10:15 am


Speaker: Dr. V. A. Shiva Ayyadurai, Ph. D., Chairman and CEO, CytoSolve, Inc.

Sample Case Study


CYTOSOLVE CASE STUDY: Neuro-Myelitis Optica (NMO)

GJCF-logoGuthy-Jackson Charitable Foundation (GJCF), focuses basic research in understanding the pathogenesis of NMO for effective prevention and therapy. NMO, a rare auto-immune disorder targets the spinal cord and optic nerves. It is characterized by the antibody IgG targeting against aquaporin 4, the major water channel in the central nervous system (CNS). The prevalence of NMO in U.S population is estimated to be 1 to 2%. The main obstacles in developing new therapeutics are complexity of human immune system and the different scenario of immune system signaling in other mammals like rats to carry out fundamental research on auto-immune disorders. GJCF proposed a blueprint – the framework of signaling pathways involved in the pathogenesis of NMO to overcome the challenges in therapeutic development. CytoSolve transformed the framework of molecular pathways into in silico models to facilitate the integrative continuum model. CytoSolve employed computational biology approach to model signal transduction pathways between astrocytes, dendritic cells, T-cells, and B-cells. Integration of multi-signaling pathways correlated the role of aquaporin antibodies IgG in inducing the activation of different cytokines like interleukins 2, 4, 8, 10, 13.